"The treatment groups showed no difference, compared with the placebo group, for the ACR20, ACR50, and ACR70 measurements, but for two other measures, the Health Assessment Questionnaire and the 28-joint Disease Activity Score, the results showed trends toward dose-related improvements following MPC treatment."
You need to be very, very careful about reading too much into trends associated with self assesment questionaires not in keeping with observed results.
It really doesn't constitute "strong" evidence. If its "evidence" at all its in the "hearsay" category.
Those are "kinds of evidence", Your Honor...
Maxim Research - New York, page-21
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.023(1.64%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.41 | $1.38 | $1.609M | 1.152M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 9340 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 152965 | 6 |
View Market Depth
| Last trade - 12.06pm 17/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |